Idorsia
Jean-Paul Clozel is the current CEO of Idorsia. Prior to this, they worked for Actelion Pharmaceuticals Ltd from January 2010 to June 2017 as a Senior Scientific Associate in CV pharmacology. Jean-Paul's responsibilities included drug testing on hypertensive rat models, establishing surgically-induced endometriosis-like lesions rat models, and catheterization of vessels for blood pressure measurements in rats & mice. Jean-Paul also conducted vascular reactivity studies of macro and micro-vessels (arteries & veins) of rats and mice.
Jean-Paul Clozel has a University certificate of Animal Experimentation Level 1 from the Faculty of Pharmacy in Nancy France. Jean-Paul also has a Master's degree in Safety Pharmacology-Pre Clinical Drug Expertise from the same school. Lastly, they have a Science degree in Cell Biology and Physiology from the Faculty of Sciences in Reims France.
Olivier Lambert - SVP, Head of Global Pharmaceutical Development & Quality Assurance, Oliver Peinelt - SVP, Group General Counsel, and Simon Jose - EVP, Chief Commercial Officer report to Jean-Paul Clozel.
This person is not in any offices
Idorsia
4 followers
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.